BBIO BridgeBio Pharma, Inc. Insider Trading

Director Andrea Ellis sold 17,167 shares of BBIO at $84.00 on 2026-07-09 (43.2% reduction); stock up 24.4% in 30 days under scheduled 10b5-1 plan

Andrea Ellis, a director of BridgeBio Pharma, sold 17,167 shares at $84.00 under a pre-arranged 10b5-1 trading plan adopted on 2025-12-03, reducing her non-derivative holdings by 43.2% from 39,746 to 22,579 shares. The sale occurred as BBIO stock gained 24.4% over the prior 30 days and currently trades at $83.08, down 11.1% from its 52-week high of $93.42. Ellis retains 17,167 shares via stock options, so her full position remains intact via derivative holdings. The company is unprofitable (net income of $-166,555,000 on revenue of $194,515,000 in the latest quarter) but shows strong annual revenue growth of 126.3%; investors should note that this sale is scheduled rather than discretionary, and Ellis's prior same-ticker sales at BBIO showed mixed 90-day outcomes (-1.5% and +26.8%), providing limited directional signal.

Director Jennifer E. Cook sells 148,589 shares for $13,156,008.00 via scheduled 10b5-1 plan at BBIO

Jennifer E. Cook, a Director at BridgeBio Pharma, executed 2 separate sales totaling 148,589 shares for $13,156,008.00 on 2026-07-09, reducing her non-derivative holdings from 156,972 shares to 8,383 shares. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2026-03-16, making it scheduled rather than discretionary. The company reported a net loss of $-166,555,000.00 in its most recent period and remains unprofitable over its most recent full fiscal year, though annual revenue growth reached +126.3%. The stock is currently trading at $83.08, down -11.1% from its 52-week high of $93.42, and Cook's sales at blended average prices of $88.54 occurred near the upper range of recent price action.

Director Jennifer E. Cook sold 39.4K shares of BBIO for $2.8M via 2 separate sales (June 23–24, 2026), 82.4% of pre-transaction holdings, under 10b5-1 plan.

Jennifer E. Cook, a director at BridgeBio Pharma, executed 2 separate sales totaling 39,363 shares for $2,752,269.72 on June 23–24, 2026, at an average of $69.92 per share. The sales reduced her non-derivative holdings from 47,746 shares to 8,383 shares, representing an 82.4% reduction in that portion of her position. However, the FLAG indicates this activity was scheduled under a 10b5-1 trading plan adopted on 2026-03-16, meaning the sales were pre-arranged and not discretionary timing decisions by the director. The insider retains 41,444 shares in derivative form (stock options), so her economic interest in the company remains substantial. At a company with $13.6B market cap and most recent quarterly revenue of $194.5M but a full-year net income of $-166.6M, scheduled open-market sales of this magnitude warrant monitoring, particularly alongside her prior sales on 2026-06-15. The current stock price of $69.36 sits 18.3% below the 52-week high of $84.94, providing context for the execution price but not explaining the underlying schedule.

BridgeBio Director Jennifer E. Cook sold 90,240 shares ($6.0M) via scheduled 10b5-1 plan on 2026-06-15

Director Jennifer E. Cook executed 2 separate sales totaling 90,240 shares for $6,012,157.06 under a pre-arranged 10b5-1 trading plan adopted on 2026-03-16, reducing her non-derivative holdings from 96,829 to 6,589 shares. The sales occurred at blended average price $66.62, below the current price of $67.39 and the 52-week high of $84.94. Cook retains significant derivative holdings of 73,334 shares in stock options, maintaining material upside exposure. BridgeBio remains unprofitable with a net loss of $-166,555,000.00 in its latest fiscal year, despite strong revenue growth of 126.3% year-over-year; the scheduled nature of this sale through a 10b5-1 plan constrains interpretation of the timing relative to the company's fundamentals.

CEO Neil Kumar sells 80,000 BBIO shares for $5.4M under pre-arranged 10b5-1 plan on 2026-06-04/05

Neil Kumar, Chief Executive Officer of BridgeBio Pharma, executed 14 separate sales totaling 80,000 shares for $5,413,288.79 at a blended average price of $67.67 across June 4–5, 2026. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-03-31, meaning the sales were scheduled in advance and not discretionary decisions. Kumar retains 4,318,447 shares post-transaction, representing a -1.8% reduction in his holdings. The company is unprofitable with net income of $-166,555,000.00 on quarterly revenue of $194,515,000.00, though annual revenue growth stands at +126.3%. The stock currently trades at $67.37, -20.7% from its 52-week high of $84.94 and -9.4% over the past 90 days, placing the transaction near recent lows within the year's range.

CEO Neil Kumar sold 26,103 shares for $1.8M (blended avg $69.44) on 2026-05-21 under pre-arranged 10b5-1 plan.

CEO Neil Kumar executed five separate sales totaling 26,103 shares for $1,812,521.76 on a single trading date, reducing his holdings by 9.7% to 243,327 shares. This transaction was scheduled under a pre-arranged 10b5-1 trading plan adopted on 2025-03-31, meaning it was not a discretionary decision but part of a predetermined execution schedule. The stock currently trades at $67.73, down 20.3% from its 52-week high of $84.94 and off 7.6% over the past 30 days, though it has gained 1.8% over 90 days. BridgeBio remains unprofitable with a $-166.6M net loss in the most recent quarter against $194.5M in revenue, though the company has achieved 126.3% annual revenue growth. Since this sale was scheduled rather than discretionary, it does not signal conviction or concern about near-term valuation; investors should focus instead on the company's fundamental trajectory as a high-growth but currently loss-making pharma organization.

BridgeBio CFO Thomas Trimarchi sells 13,651 shares for $888.4K via scheduled 10b5-1 plan on 2026-05-18

Thomas Trimarchi, President and CFO of BridgeBio Pharma, executed two separate sales totaling 13,651 shares for $888,419.17 on 2026-05-18, reducing his holdings by 3.7% to 359,194 shares post-transaction. The sales were executed through a pre-arranged 10b5-1 trading plan adopted on 2025-03-31, meaning the transactions were scheduled rather than discretionary. At BBIO specifically, Trimarchi's prior four measurable sales show mixed outcomes: two sales in February 2026 experienced 30-day declines of 6.2% and 7.0%, while two November 2025 sales saw 30-day gains of 11.8% and 10.7%. The company's fundamentals remain challenged: full-year net income was $-166.6M against quarterly revenue of $194.5M, though annual revenue growth reached +126.3%. Stock price is currently -22.3% from its 52-week high and down 14.0% over 30 days, reflecting the unprofitable operational status despite strong top-line expansion.

BridgeBio CEO Kumar Neil sells ~$5.4M of stock (80,000 shares) via 12 transactions; his 126th-137th open-market sale in 3 years, no purchases.

Kumar Neil, BridgeBio's CEO, sold approximately 80,000 shares over two trading days in early May totaling roughly $5.4M—his 126th through 137th open-market sale in the past three years, with zero open-market purchases in that period. The stock currently trades roughly 15% below its 52-week high and has declined modestly over the past three months, creating a backdrop where the CEO is choosing to reduce his position. His five prior sales at BridgeBio were all followed by stock declines, demonstrating consistent timing accuracy on those exits. The company is unprofitable on an annual basis, though quarterly results show a modest loss, alongside strong revenue growth that has more than doubled year-over-year, suggesting a cash-intensive growth business. The sale itself is not unusual for a pharmaceutical company burning cash, but the three-year pattern of continuous selling and complete absence of any open-market purchases is noteworthy for someone running the company—it reflects a persistent divestiture posture rather than conviction in the business or willingness to put personal capital at risk.

CEO Kumar Neil sold 80,000 shares of BBIO for $5,968,780.09 via scheduled 10b5-1 plan on 2026-04-09–10

Kumar Neil, CEO of BridgeBio Pharma, executed 8 separate sales totaling 80,000 shares for $5,968,780.09 at prices ranging from $73.64 to $75.55, reducing his holdings from 4,478,447 shares to 4,398,447 shares (-1.8%). This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-03-31, meaning the sales were scheduled and not discretionary in timing or execution. The CEO retains substantial post-transaction holdings of 4,398,447 shares, indicating continued material ownership alignment with the company. As a scheduled plan, this sale carries no implications about the insider's current conviction or market outlook.

BridgeBio CEO Kumar Neil sells 80,000 shares for $5.5M via scheduled 10b5-1 plan on 2026-03-12 to 2026-03-13

Kumar Neil, Chief Executive Officer of BridgeBio Pharma, executed 10 separate sales totaling 80,000 shares for $5,501,068.07 across two trading dates (2026-03-12 and 2026-03-13), with transactions priced between $68.36 and $70.15 per share and a blended average price of $68.76. This sale represents a 1.8% reduction in his post-transaction holdings of 4,438,447 shares, bringing his total shareholding from 4,518,447 shares. The transaction was executed pursuant to a pre-arranged 10b5-1 trading plan adopted on 2025-03-31, indicating the timing and volume were determined in advance and do not reflect discretionary decision-making. As a scheduled divestiture under a pre-existing plan, this sale provides limited direct signals about near-term company fundamentals or the CEO's current confidence posture.